Death
Drugs: BLENREP
- Safetyreportversion
- 1
- Safetyreportid
- 27325223
- Primarysourcecountry
- JP
- Occurcountry
- JP
- Transmissiondateformat
- 102
- Transmissiondate
- 20261010
- Reporttype
- 1
- Serious
- 1
- Seriousnessdeath
- 1
- Seriousnesslifethreatening
- 2
- Seriousnesshospitalization
- 2
- Seriousnessdisabling
- 2
- Seriousnesscongenitalanomali
- 2
- Seriousnessother
- 1
- Receivedateformat
- 102
- Receivedate
- 20260930
- Receiptdateformat
- 102
- Receiptdate
- 20260930
- Fulfillexpeditecriteria
- 1
- Companynumb
- JP-GSKJP-JP2026JPN128946AA
- Primarysource
- Reportercountry
- JP
- Qualification
- 5
- Sender
- Sendertype
- 6
- Senderorganization
- GLAXOSMITHKLINE
- Receiver
- Receivertype
- 6
- Receiverorganization
- FDA
- Patient
- Reaction
- Reactionmeddraversionpt
- 29.0
- Reactionmeddrapt
- Death
- Reactionoutcome
- 5
- Drug
- Drugcharacterization
- 1
- Medicinalproduct
- BLENREP
- Drugbatchnumb
- UNK
- Drugauthorizationnumb
- 761440
- Drugseparatedosagenumb
- 1
- Drugdosagetext
- UNK
- Actiondrug
- 6
- Drugrecurreadministration
- 3
- Drugadditional
- 4
- Activesubstance
- Activesubstancename
- BELANTAMAB MAFODOTIN-BLMF
- Drugcharacterization
- 1
- Medicinalproduct
- BLENREP
- Drugbatchnumb
- UNK
- Drugauthorizationnumb
- 761440
- Drugseparatedosagenumb
- 1
- Drugdosagetext
- UNK
- Actiondrug
- 6
- Drugrecurreadministration
- 3
- Drugadditional
- 4
- Activesubstance
- Activesubstancename
- BELANTAMAB MAFODOTIN-BLMF
